Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to assess the expression of TLR 3, 7, and 9 in the population of peripheral blood mononuclear cells (PBMC) and in B lymphocytes (CD19+), T lymphocytes (CD4+ and CD8+) using flow cytometry in relation to the clinical parameters and outcome of COVID 19 patients .


Clinical Trial Description

Abnormal stimulation of innate immunity may have a great influence on the immunopathogenesis of COVID 19 disease .The involvement of innate immunity receptors-toll-like receptors (TLR)-in the pathogenesis of COVID 19 is not adequately studied. The activation of these receptors by specific ligands is thought to initiate autoimmune processes[1]. TLR stimulation leads to increased expression of proinflammatory cytokines (IL-6, IFN ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05089110
Study type Observational
Source Assiut University
Contact Fady Markos, resident doctor
Phone 01203456886
Email fadyfedo3296@gmail.com
Status Not yet recruiting
Phase
Start date November 1, 2021
Completion date November 1, 2024